Literature DB >> 33972182

Acute and late side-effects after low dose-rate brachytherapy for prostate cancer; incidence, management and technical considerations.

Joelle Helou1, Tomer Charas2.   

Abstract

PURPOSE: To review common reported side effects and complications after primary LDR-BT (monotherapy) and discuss some of the technical aspects that could impact the treatment outcomes. METHODS AND MATERIALS: A literature search was undertaken using medical subject headings (MeSH) complemented by the authors' personal and institutional expertise.
RESULTS: The reported incidence of acute and late grade 2 or above urinary, bowel and sexual side effects is very variable across the literature. The learning curve and the implant quality have a clear impact on the toxicity outcomes. Being aware of some of the technical challenges encountered during the procedure and ways to mitigate them could decrease the incidence of side effects. Careful planning of seed placement and seed deposition allow sparing of the organs at risk and a lower incidence of urinary and gastro-intestinal toxicity.
CONCLUSIONS: Low dose-rate brachytherapy remains a standard monotherapy treatment in the setting of favorable-risk prostate cancer. High disease control and low long-term toxicities are achievable in expert hands with a good technique.
Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Low dose-rate; Prostate cancer; Technical challenges; Toxicity

Year:  2021        PMID: 33972182     DOI: 10.1016/j.brachy.2021.03.014

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  2 in total

1.  High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up.

Authors:  Manuel Behmueller; Nikolaos Tselis; Nikolaos Zamboglou; Eleni Zoga; Dimos Baltas; Claus Rödel; Georgios Chatzikonstantinou
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

2.  Cancer Survivors' Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q).

Authors:  Katharina M D Merollini; Louisa G Gordon; Yiu M Ho; Joanne F Aitken; Michael G Kimlin
Journal:  Int J Environ Res Public Health       Date:  2022-08-02       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.